XChara Consulting logo

Vision & Mission

Integrated DMPK, translational science, clinical pharmacology, and model-informed
development leadership for emerging biotech teams that need strategic thinking and hands-on execution.

Discovery → IND → Phase I/II → Registration
Engaged strategic and hands-on support
Efficient fit-for-purpose modeling and simulation
Expertise in helping lean biotech teams

The Evolution of Clinical Pharmacology: We Can Do More

From descriptive science to predictive, integrated decision-making

⚗

The Beginning

1960s–1980s
  • Descriptive PK
  • Single-dose studies
  • Focus on disposition
▥

The Foundation

1990s
  • PK/PD concepts
  • Early modeling
  • Exposure-response
👥

The Expansion

2000s
  • Population PK
  • DDI evaluation
  • Special populations
  • Regulatory science grows
▣

The Integration

2010s
  • Model-informed drug development
  • Translational integration
  • Cross-functional strategy
⌘

The AI-Enhanced Era

2020s and beyond
  • AI/ML and real-world data
  • Digital health and decentralized trials
  • Predictive, adaptive learning
Clinical pharmacology has evolved into a strategic, innovative, translational, quantitative, and patient-centric discipline that integrates data into better decisions across the full path of drug development.

Clinical Pharmacology: Collaborating Across the Ecosystem

Integrated science. Shared goals. Better outcomes.

🔬

Translational Science

  • Biology and targets
  • Translational data
  • Early hypotheses
◕

Nonclinical DMPK/Tox

  • PK/PD in models
  • Safety assessment
  • Dose selection
👥

Clinical Operations

  • Study execution
  • Data quality
  • Timelines
●

Medical Strategy

  • Indication strategy
  • Evidence planning
  • Medical communications
Clinical PharmacologyBridging science and strategy across functions
▥

Biostatistics

  • Study design
  • Analysis plans
  • Data interpretation
  • Modeling and simulation
□

Regulatory Affairs

  • Regulatory strategy
  • Submissions
  • Agency interactions
✚

Safety / PV

  • Safety monitoring
  • Benefit-risk assessment
  • Signal evaluation
◎

Commercial & Real-World Insights

  • Value proposition
  • Market access
  • RWE integration
Aligned expertise. Clear communication. Faster decisions. Greater impact.

A Generic Clinical Pharmacology Plan

A risk-based, fit-for-purpose roadmap

⌕

Discovery & Preclinical

  • Mechanism, PK/PD
  • Candidate selection
  • Early modeling
  • DMPK assessment
🧪

IND Enabling (Pre-IND)

  • First-in-human plan
  • Dose selection
  • Safety and tolerability
  • Bioanalytical strategy
👥

Early Clinical (Ph I)

  • PK, PD, exposure-response
  • Population PK
  • Safety & DDI assessments
  • Go/no-go inputs
👥👥

Late Clinical (Ph II–III)

  • Dose optimization
  • DDI assessments
  • Special populations
  • Benefit-risk evaluation
  • Labeling support
✓

Registration & Lifecycle

  • Regulatory submission
  • Post-approval studies
  • RWE and outcomes
  • Lifecycle management

Small Molecules

  • DDI and metabolism
  • Food effect
  • BE / rBA
  • 14C ADME

Biologics

  • Immunogenicity (ADA)
  • TMDD
  • Long half-life

Cell & Gene Therapies

  • Biodistribution
  • Persistence
  • Transgene kinetics

Radiopharmaceuticals

  • Dosimetry
  • Organ exposure
  • Radiation safety
One integrated and adaptive plan, based on available data, development stage, regulatory requirements, competitive considerations, risk assessment, and investment gating.

Clinical Pharmacology: From Design to Impact

Integrated. Quantitative. Patient-centered.

☑

Design

  • Optimize study design
  • Define endpoints
  • Select dose and regimen
  • Plan analyses and simulations
  • Select vendors and CROs
▦

Execute

  • Anticipate and resolve issues
  • Manage vendors
  • Oversee conduct and data quality
  • Manage budget and timeline
▤

Analyze

  • Preliminary analysis
  • Review TFLs, data and CSR
  • PK/PD and exposure-response
  • Modeling: PK/PD, PPK, PBPK
  • Interpret results
↗

Impact

  • Achieve objectives
  • Guide next studies
  • Inform strategy and portfolio
  • Support decisions
  • Create value
The right study. The right insight. The right decision. The right impact.

Dose Optimization: A Data-Informed, Model-Informed Approach

Right dose. Right patient. Right schedule.

Dose optimization workflow connecting strategy, data generation, analysis, iterative learning, and development decisions
Dose optimization should connect evidence, uncertainty, clinical objectives, patient benefit-risk, regulatory expectations, and lifecycle strategy.